NCT04754776View on ClinicalTrials.gov

Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2022

Conditions

Rift Valley Fever

Interventions

BIOLOGICAL

ChAdOx1 RVF

Single dose of ChAdOx1 RVF

Trial Locations (1)

OX3 7LE

CCVTM, University of Oxford, Churchill Hospital, Oxford

All Listed Sponsors

lead

University of Oxford

OTHER